F-star, a leader in the development of novel bispecific antibodies, is pleased to announce the appointment of Dr. John Haurum as Chief Executive Officer. John will be taking over from Dr. Kevin FitzGerald, who is stepping down from the position to pursue new opportunities. Also joining the management team is [...]
Terms include $650 million in cash plus a potential $50 million milestone payment Transaction would be immediately accretive to Jazz Pharmaceuticals’ adjusted EPS would add significant U.S. marketed product, Erwinaze™ (asparaginase Erwinia chrysanthemi), a life-saving treatment for a form of leukemia that primarily affects children Combined company to market diversified [...]
Hamburg, Germany – 26 April 2012: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has extended and expanded its medicinal chemistry collaboration with Active Biotech AB (NASDAQ OMX: ACTI), to further advance an existing programme, which has entered the lead optimisation phase. The programme aims to find [...]
- Nature-Veröffentlichung zeigt: Nervenschädigung wird von Pyroglutamat Abeta (Aβ) ausgelöst und ist abhängig vom tau-Protein – Pyroglutamat Aβ (“pyroGluAβ”) ist ein giftiges Proteinfragment der sogenannten Aβ-Peptidablagerungen im Gehirn von Alzheimer-Patienten. Es führt zur Bildung von sogenannten niedermolekularen Oligomeren (LMO), noch stärker giftigen Zusammenlagerungen, die sich ähnlich wie Prionen entlang der [...]
–Arcelis™ Immunotherapy AGS-003 Granted U.S. FDA Fast Track Designation for Treatment of mRCC– Durham, NC– April 24, 2012 —Argos Therapeutics Inc. today announced that it has secured a $25 million Series D financing to support the commencement of its Phase 3 ADAPT study in patients with newly diagnosed, metastatic renal [...]
- More than 90 Percent of Patients New to HCV Treatment Achieved Sustained Viral Response through 12 Weeks – ABBOTT PARK, Ill., and Watertown, Mass., Apr. 19, 2012 – Abbott and Enanta Pharmaceuticals announced data from “Co-Pilot,” an interferon-free, Phase 2 study of Abbott’s direct-acting antiviral medicines for the treatment [...]
- Results among the Most Mature Data for an Interferon-Free Regimen, Including 36-Week Post-Treatment Sustained Viral Response for a 12-Week Treatment Regimen – ABBOTT PARK, Ill., and Watertown, Mass., Apr. 19, 2012 – Abbott and Enanta Pharmaceuticals announced complete data from the study known as “Pilot” – Abbott’s initial interferon-free [...]
rogram on track for IND filing before end of 2012 GABA-BR PAM compounds have potential in several major Indications Geneva, Switzerland, 16 April 2012 – Addex Therapeutics (SIX:ADXN), a leading organization pioneering allosteric modulation-based drug discovery and development, announced today positive data from studies of its lead GABA-B receptor (GABA-BR) positive [...]
- Poster Presentations to Include Enanta’s Nucleotide HCV Polymerase Inhibitor Program and Additional ABT-450 Data – WATERTOWN, Mass., April. 4, 2012 — Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that key data from two [...]
Tokyo, Japan and Gothenburg, Sweden, April 3, 2012 Ajinomoto Pharmaceuticals Co., Ltd. (President, Tomoyasu Toyoda; Headquarters, Chuo-ku, Tokyo; “Ajinomoto Pharmaceuticals” and Albireo AB (Gothenburg, Sweden; “Albireo”) today announced that they have signed an agreement providing Ajinomoto Pharmaceuticals exclusive rights to develop and commercialize elobixibat (Development code: A3309) in Japan, South [...]